FIELD: biotechnology.
SUBSTANCE: isolated antibody or its binding fragment with a variant of the Fc region is described, the antibody or its binding fragment is able to bind to influenza A virus hemagglutinin and neutralize at least one subtype of group 1 and at least one subtype of group 2 of the influenza virus and have an increased half-life from serum compared to an antibody with a natural Fc, where the antibody or its binding fragment contains HCDR1 SEQ ID NO: 113, HCDR2 SEQ ID NO:114, HCDR3 SEQ ID NO:115, LCDR1 SEQ ID NO:118, LCDR2 SEQ ID NO:119, LCDR3 SEQ ID NO:120. The corresponding selected nucleic acid encoding the specified antibody or its binding fragment is also described. An expression vector containing said isolated nucleic acid as well as the corresponding host cell is also presented. A method for obtaining the specified antibody or its binding fragment, including culturing the host cell under conditions suitable for the expression of the antibody or its fragment is described. A composition containing the specified antibody or its binding fragment for the prevention or treatment of infection caused by the influenza A virus in an individual is described. A method for preventing or treating an influenza A virus infection in an individual is provided, comprising administering to the individual an effective amount of an antibody or binding fragment thereof is presented.
EFFECT: invention expands the arsenal of means for combating the influenza A virus.
22 cl, 15 dwg, 13 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS THAT BIND TO DR5 | 2016 |
|
RU2748620C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
